Mutual of America Capital Management LLC Lowers Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mutual of America Capital Management LLC cut its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,519 shares of the biopharmaceutical company’s stock after selling 168 shares during the period. Mutual of America Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $291,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. U.S. Capital Wealth Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $10,892,000. Harbor Capital Advisors Inc. increased its position in shares of Alnylam Pharmaceuticals by 6.0% during the third quarter. Harbor Capital Advisors Inc. now owns 2,887 shares of the biopharmaceutical company’s stock valued at $511,000 after acquiring an additional 163 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Alnylam Pharmaceuticals by 9.1% during the third quarter. Commonwealth Equity Services LLC now owns 4,372 shares of the biopharmaceutical company’s stock valued at $774,000 after acquiring an additional 363 shares in the last quarter. Xponance Inc. increased its position in shares of Alnylam Pharmaceuticals by 0.7% during the third quarter. Xponance Inc. now owns 14,984 shares of the biopharmaceutical company’s stock valued at $2,654,000 after acquiring an additional 109 shares in the last quarter. Finally, Raymond James & Associates increased its position in shares of Alnylam Pharmaceuticals by 5.1% during the third quarter. Raymond James & Associates now owns 12,411 shares of the biopharmaceutical company’s stock valued at $2,198,000 after acquiring an additional 598 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $146.07 on Wednesday. The company’s fifty day simple moving average is $151.09 and its 200-day simple moving average is $166.50. The stock has a market capitalization of $18.40 billion, a PE ratio of -41.03 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1-year low of $143.50 and a 1-year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The firm had revenue of $439.72 million for the quarter, compared to analysts’ expectations of $439.38 million. During the same quarter last year, the firm posted ($1.68) EPS. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $235.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Chardan Capital cut their target price on shares of Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, February 16th. The Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $230.00 to $173.00 in a research report on Friday, February 16th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $165.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a research report on Thursday, February 1st. Nine equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $216.12.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.